Learning disabilities

M&T Bank and Life-Skills App Magnusmode Collaborate to Support Customers with Autism, Cognitive and Intellectual Disabilities

Retrieved on: 
Tuesday, June 15, 2021
Psychiatry, Psychiatric diagnosis, Abnormal psychology, Learning disabilities, Branches of biology, Pervasive developmental disorders, Neurological disorders, Childhood psychiatric disorders, Autism, Disability, Dementia, Attention deficit hyperactivity disorder

"We are excited to work with Magnusmode not only because they're an inspiring local startup, but also because their product is incredibly intuitive and well-designed to support our customers."

Key Points: 
  • "We are excited to work with Magnusmode not only because they're an inspiring local startup, but also because their product is incredibly intuitive and well-designed to support our customers."
  • Using digitalized "Card Decks," the MagnusCards app guides users through tasks and activities that might otherwise feel challenging or overwhelming.
  • The app's users include people with autism, down syndrome, acquired brain injury, dementia, ADHD and other cognitive disabilities.
  • "Confusing or complex services can create barriers for people with autism and other cognitive disabilities.

New Treatment Stops Progression of Alzheimer's Disease in Monkey Brains

Retrieved on: 
Tuesday, June 15, 2021
Branches of biology, Medicine, Psychiatric diagnosis, Psychiatry, Cognitive disorders, Learning disabilities, Amyloidosis, Abnormal psychology, Alzheimer's disease, Disease, Dementia, Gladstone Institutes

This nerve fiber protein can destroy neighboring tissue when disease-related changes to its chemical structure causes it to catch on other cells.

Key Points: 
  • This nerve fiber protein can destroy neighboring tissue when disease-related changes to its chemical structure causes it to catch on other cells.
  • The investigators say the treatment led to cognitive benefits as well.
  • Alzheimer's disease is the sixth leading cause of death in the United States and has no known cure.
  • Further testing on younger animals, she notes, would allow them to assess the effectiveness of the treatment in earlier stages of the disease.

Cognito Therapeutics Initiates Studies in Down Syndrome Associated Alzheimer’s Disease

Retrieved on: 
Monday, June 14, 2021
Health, Other Science, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Branches of biology, Biology, Learning disabilities, Psychiatric diagnosis, Neurological disorders, Neuroscience, Alzheimer's disease, Dementia, Neurodegeneration

Cognito Therapeutics , a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders including Alzheimers disease, announced today its plans to add a second digital therapeutic to the companys pipeline, initiating a new study evaluating digital therapeutic for individuals who have the genetic rare disease, Down syndrome associated Alzheimers Disease (DS-AD).

Key Points: 
  • Cognito Therapeutics , a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders including Alzheimers disease, announced today its plans to add a second digital therapeutic to the companys pipeline, initiating a new study evaluating digital therapeutic for individuals who have the genetic rare disease, Down syndrome associated Alzheimers Disease (DS-AD).
  • Roughly half of the participants with Down syndrome indicated having symptoms of cognitive decline associated with Alzheimers disease or had a confirmed diagnosis.
  • Down Syndrome associated Alzheimers Disease is a genetically associated, aggressive form of Alzheimers where individuals with Down syndrome are born with an extra copy of chromosome 21, which carries a gene that produces a specific protein called amyloid precursor protein (APP).
  • Cognito Therapeutics is a clinical-stage company developing a pipeline of disease-modifying digital therapeutics that have shown drug-like effects to treat neurodegenerative disorders including Alzheimers disease.

Anavex Life Sciences Reports New Publication in Medical Journal Elucidating the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) related to the Treatment of Alzheimer's Disease

Retrieved on: 
Monday, June 14, 2021
Psychiatric diagnosis, Branches of biology, Psychiatry, Medicine, Cognitive disorders, Learning disabilities, Aging-associated diseases, Dementia, Parkinson's disease, Alzheimer's disease, Rett syndrome, Frontotemporal dementia

The publication explains that AD is a multifactorial disease, where several pathways interlink with each other and cause cognitive impairments.

Key Points: 
  • The publication explains that AD is a multifactorial disease, where several pathways interlink with each other and cause cognitive impairments.
  • The available drugs only tend to target a single pathway and mitigate the symptoms of AD without slowing the disease progression.
  • Combinatorial therapy has been suggested as a treatment strategy; however, the existence of drug-drug interaction is a concern.
  • Anavex Life Sciences product portfolio platform includes small molecule drug lead candidate ANAVEX2-73 for the treatment of Alzheimers disease, Parkinsons disease and Rett syndrome and ANAVEX3-71 for frontotemporal dementia.

EarlyBird Education Introduces Game-Based Screener to Help Schools Identify Children at Risk for Dyslexia and Reading Difficulties — Even Before They Learn to Read

Retrieved on: 
Monday, June 14, 2021
Software, Other Education, Technology, Electronic Games, Primary, Secondary, Education, Training, Entertainment, Education, Educational psychology, Articles, Learning, Reading, Special education, Learning to read, Learning disabilities, Dyslexia, Reading disability

To help schools identify children at risk for reading difficulties before they start struggling with reading, EarlyBird Education today announces the nationwide release of the EarlyBird game-based screener.

Key Points: 
  • To help schools identify children at risk for reading difficulties before they start struggling with reading, EarlyBird Education today announces the nationwide release of the EarlyBird game-based screener.
  • It helps educators identify and support children at risk for dyslexia and other reading difficulties even before they learn to read.
  • Reading difficulties such as dyslexia are generally diagnosed in second or third grade, after repeated failure to learn to read and after the most effective intervention window, said Carla Small, co-founder and CEO of EarlyBird Education.
  • With EarlyBird, educators can identify children at risk for reading difficulties in the window when intervention is most effective before they formally learn to read.

Alzheimer's Association Statement: Next Steps For New Alzheimer's Treatment

Retrieved on: 
Saturday, June 12, 2021
Branches of biology, Aphasias, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Psychiatry, Medicine, Alzheimer's Association, Food and Drug Administration, Alzheimer's disease

Alzheimer's Association's research experts and advisors are deeply familiar with the basic and regulatory science that led to the FDA's decision.

Key Points: 
  • Alzheimer's Association's research experts and advisors are deeply familiar with the basic and regulatory science that led to the FDA's decision.
  • Additionally, the FDA appropriately took into account the vast unmet need of the Alzheimer's community.
  • Aduhelm is certainly not a cure, but at long last it provides many with Alzheimer's disease and their families an effective treatment.
  • Our focus has and will continue to be access to this treatment for all likely to benefit.

Unlocking the Genius of Autism -New School Opens in Riverhead

Retrieved on: 
Friday, June 11, 2021
Branches of biology, Psychiatric diagnosis, Psychiatry, Neuroscience, Learning disabilities, Autism, Autism spectrum, Developmental neuroscience, Developmental psychology

RIVERHEAD, N.Y., June 11, 2021 /PRNewswire/ --Acton Academy Eastern Long Island today announced the first phase of the Autism Studio launching July 6, 2021 in Riverhead, NY.

Key Points: 
  • RIVERHEAD, N.Y., June 11, 2021 /PRNewswire/ --Acton Academy Eastern Long Island today announced the first phase of the Autism Studio launching July 6, 2021 in Riverhead, NY.
  • It is a revolutionary new program that seeks to unlock this highly intelligent, grossly misunderstood population.
  • The Autism Studio, phase one, will begin this July, inviting non-speaking and minimally-speaking autistic individuals to learn S2C.
  • Andrea has published two books on autism, Autism A New Humanity (Hay House 2015) and Autism: A New Perspective (KDP 2019) which she co-authored with a non-verbal autist from Portugal.

Acorn Health Acquires LEAP Behavior Analysis in Tennessee

Retrieved on: 
Thursday, June 10, 2021
Children, Health, Mental health, Consumer, Mind, Psychology, Self, Psychiatric diagnosis, Autism, Learning disabilities, Neurological disorders, Behaviorism, Autism spectrum, Applied behavior analysis, Acorn Computers, Draft:Hopebridge Autism Therapy Centers

Acorn Health, a national provider of Applied Behavior Analysis (ABA) therapy for children diagnosed with Autism Spectrum Disorder (ASD), is pleased to announce the acquisition of substantially all of the assets of LEAP Behavior Analysis (LEAP or the Company).

Key Points: 
  • Acorn Health, a national provider of Applied Behavior Analysis (ABA) therapy for children diagnosed with Autism Spectrum Disorder (ASD), is pleased to announce the acquisition of substantially all of the assets of LEAP Behavior Analysis (LEAP or the Company).
  • The Company is now a wholly-owned subsidiary of Acorn Health of Tennessee, and will operate under the Acorn Health brand.
  • We are excited to welcome LEAP into the Acorn Health network of high-quality ABA centers, said Vicki Kroviak, CEO of Acorn Health.
  • Acorn Health is a national provider of applied behavior analysis (ABA) therapy for children diagnosed with Autism Spectrum Disorder with locations in Michigan, Illinois, Virginia, Florida, Maryland, Pennsylvania, and Tennessee.

Joanne Garland's new book "A Pink Mountain: Like Mother, Like Son" is an inspirational memoir of a mother and son who both struggle with autism's stigmas and strife

Retrieved on: 
Wednesday, June 9, 2021
Branches of biology, Psychiatric diagnosis, Psychiatry, Neuroscience, Learning disabilities, Autism

Joanne writes, "I guess it's ironic that a person with such a deep capacity for understanding others, especially those who are the most misunderstood would be so misunderstood herself.

Key Points: 
  • Joanne writes, "I guess it's ironic that a person with such a deep capacity for understanding others, especially those who are the most misunderstood would be so misunderstood herself.
  • But, as it appears to be, in my opinion, most, if not all people with some form of autism, are misunderstood by people who are, shall we say ignorant.
  • Published by Page Publishing, Joanne Garland's inspirational tale dives deeply into her personal struggles with the stigma attached to autism.
  • In her studies, Garland came to a chilling realization, the signals and situations speaking to her, that she too, was on the spectrum.

First new treatment for Alzheimer's disease approved in nearly two decades offers hope for people living with dementia

Retrieved on: 
Monday, June 7, 2021
Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Psychiatry, Branches of biology, Dementia, Health, Alzheimer Society of Canada, Alzheimer's disease, Alzheimer Society of Ontario, Art and dementia

"Over the next 10 years, we anticipate that more than one million people in Canada will be living with dementia.

Key Points: 
  • "Over the next 10 years, we anticipate that more than one million people in Canada will be living with dementia.
  • There is an urgent need to investin dementia research to provide people living with the disease new and better treatments.
  • The Alzheimer Society of Canada is committed to funding innovative dementia research focused on prevention, diagnosis, treatment, and finding cures for Alzheimer's disease and other dementias.
  • The Alzheimer Society Research Program is Canada's leading funder of research into better understanding the causes of dementia, improving treatment and care, and towards finding cures.